And this -- speed to identify both promising avenues, and/or dead ends -- will likely save Merck into the billions of dollars, over the next five to ten years. Well worth it. [Especially as compared to a "one-trick pony" vapor-ware / web 3.0 grab-bag of frankensteined existing software -- now being offered by the felon Martin Shkreli, under the name "druglike". Heh.] Here's the bit:
. . .Saama Technologies, LLC. (“Saama”) today announced a multi-year agreement with Merck, known as MSD outside the United States and Canada, to build and operationalize a new clinical data layer leveraging Saama’s Life Science Analytics Cloud (LSAC) to strengthen Merck’s clinical development capabilities and expedite pipeline progress.
“Saama and Merck share a commitment to accelerating drug development and utilizing state-of-the-art Machine Learning for clinical data management processes. We are pleased to support the clinical development efforts of one of the top biopharmaceutical companies in the world,” said Suresh Katta, Founder and Chairman Emeritus, Saama Technologies. “LSAC will enable Merck’s team to optimize and automate processes, accelerate cycle times, and reduce costs in the quest to bring new treatments to patients sooner.”
Under the agreement, Merck will integrate LSAC into its clinical development systems to improve speed and efficiency related to the ingestion, curation, and transformation of data and facilitate processing from multiple internal and external data sources to multiple business platforms and analytics needs. . . .
Now you know -- smiling, as I look forward to a french dinner out, and another. . . 38 years.
नमस्ते
No comments:
Post a Comment